RxDoctor Payments Data

Francisco Jimenez Carcamo, MD

Cardiovascular Disease · South Miami, FLNPI 1295787927

Payments from drug & device makers

$305,794in general payments, 2019–2025

Across 527 payments — averaging $580.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$73K
  • Actelion Pharmaceuticals US, Inc.$53K
  • Boehringer Ingelheim$40K
  • United Therapeutics Corporation$35K
  • Akcea Therapeutics, Inc.$25K
  • Pfizer$20K
  • plus $59K from 29 others

What the payments were for

  • Consulting fees$34,77312%
  • Speaking & faculty fees$239,28182%
  • Travel & lodging$6,3692%
  • Food & beverage$12,4394%
  • Education$4540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,794 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$372,841
Medicare patients
547
Services billed
4,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan211$2,662,176
AdempasRiociguat80$1,135,416
Orenitram ErTreprostinil Diolamine85$1,035,308
VyndamaxTafamidis30$873,821
UptraviSelexipag29$700,337
VyndaqelTafamidis Meglumine29$631,715
EntrestoSacubitril/Valsartan541$604,919
JardianceEmpagliflozin392$429,160
EliquisApixaban301$359,749
WinrevairSotatercept-Csrk17$314,076
Ambrisentan24$155,366
XareltoRivaroxaban109$115,058
FarxigaDapagliflozin Propanediol99$98,317
Repatha SureclickEvolocumab72$85,462
Tadalafil44$54,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$52,800$3,362,513240 claims
PfizerVyndamax, Vyndaqel, Eliquis$20,355$1,865,285360 claims
BayerAdempas, Kerendia$72,958$1,156,474108 claims
NovartisEntresto$119$604,919541 claims
Boehringer IngelheimJardiance$39,870$429,160392 claims
MerckWinrevair, Verquvo$9,359$338,85538 claims
Johnson & JohnsonXarelto$231$115,058109 claims
AstraZenecaFarxiga$14,494$98,31799 claims
Sanofi-aventis U.S. LLCMultaq$17$40,07926 claims
Kowa Pharmaceuticals America, Inc.Livalo$15$18,40827 claims
AmgenCorlanor$75$10,47418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →